Hepatitis-B virus: replication cycle, targets, and antiviral approaches.

Autor: Nasser N; Université Paris-Cité, Centre de recherche sur l'inflammation, Inserm U1149, Paris, France; Department of Hepatology, AP-HP, Hôpital Beaujon, Clichy, France., Tonnerre P; Université Paris-Cité, Inserm UMR 976, Human Immunology, Pathophysiology and Immunotherapy (HIPI), team ATIP-Avenir, Paris, France., Mansouri A; Université Paris-Cité, Centre de recherche sur l'inflammation, Inserm U1149, Paris, France; Department of Hepatology, AP-HP, Hôpital Beaujon, Clichy, France., Asselah T; Université Paris-Cité, Centre de recherche sur l'inflammation, Inserm U1149, Paris, France; Department of Hepatology, AP-HP, Hôpital Beaujon, Clichy, France. Electronic address: Tarik.asselah@aphp.fr.
Jazyk: angličtina
Zdroj: Current opinion in virology [Curr Opin Virol] 2023 Dec; Vol. 63, pp. 101360. Date of Electronic Publication: 2023 Sep 10.
DOI: 10.1016/j.coviro.2023.101360
Abstrakt: An estimated 257 million people are chronic carriers of hepatitis-B virus (HBV) infection, which resulted in around 1 million deaths, mainly due to hepatocellular carcinoma (HCC). Long-term nucleotide analog treatment of HBV infection is associated with favorable prognosis, no disease progression, and a reduction of HCC risk, but lifelong treatments are required. A better understanding of HBV replication cycle and the host immune response will likely improve the identification of new targets for drug development. Studies are ongoing to determine if it is possible to successfully combine direct-acting antivirals (DAA) with an immunomodulatory therapy to allow increased cure rates. This review will start with summarizing the HBV replication cycle, recall current treatments, and then discuss potential targets and antiviral approaches in development to optimistically reach the HBV cure.
Competing Interests: Declaration of Competing Interest None.
(Copyright © 2023. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: